MedicineChemistry

The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir

K. McDaniel, Y. Ku, Ying Sun, Hui-ju Chen, Jason P. Shanley, T. Middleton, Y. Or, D. Kempf

2019Topics in Medicinal Chemistry

DOI: 10.1007/7355_2018_42

tlooto Summary

The discovery and development of ABT-450 enabled one of the first IFN-free combination therapies for HCV genotype 1 infection and contributed to the transformation of the treatment of this chronic and deadly disease.

Abstract

Abstract is not available.

Citation format

MCDANIEL, K., et al. The discovery and development of HCV NS3 protease inhibitor paritaprevir. Topics in Medicinal Chemistry, 2019.